spacer
home > ebr > spring 2002 > the patenting of biotechnology in canada
PUBLICATIONS
European Biopharmaceutical Review

The Patenting of Biotechnology in Canada

Unlike in the US or Europe, there are no clear guidelines in Canada governing patenting requirements in the field of biotechnology, and case law is limited. In the absence of domestic policy or law, the Canadian Patent Office is greatly influenced by the practices of the US and European patent offices. This approach has been endorsed by the Canadian courts, who have frequently turned to other jurisdictions for guidance when domestic law is lacking. In recent decisions, such as the Federal Court Trial Division in Monsanto Canada Inc. versus Schmeiser (2001), 12 C.P.R. (4th) 204 (F.C.T.D.); the Federal Court of Appeal in The President and Fellows of Harvard College versus Canada (Commissioner of Patents) (2000), 7 C.P.R. (4th) 1 [hereinafter Harvard College, Supra]; and the Supreme Court of Canada in Free World Trust versus Electro Sante Inc. (2000), 9 C.P.R. (4th) 168, the Courts espoused the value of referring to US case law and practice to provide guidance in the development of Canadian patent law.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Anita Nador, Partner in the Biotechnology and Pharmaceutical Practice Group at Bereskin & Parr

Anita Nador is a Partner with Bereskin & Parr in their Biotechnology and Pharmaceutical Practice Group. She received a BA in Molecular Biophysics and Biochemistry from Yale University in 1986 and undertook research at Harvard Medical School and at a major Canadian pharmaceutical company before obtaining a Law degree from the University of Toronto in 1993.
Anita was called to the bar of Ontario in 1995 and is a registered Canadian patent and trademark agent. She is also registered to practice before the US Patent Office. Anita's practice is specialised in the area of intellectual property - particularly in biotechnology and pharmaceutical patent - plant breeders' rights, and trademark and licensing matters.

spacer
Anita Nador
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement